SHYNDEC(SH:600420) Shang Hai Zheng Quan Bao·2025-09-12 19:28Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd. is actively engaging with investors through a performance briefing and has received regulatory approvals for its products, indicating a focus on transparency and growth in the pharmaceutical sector [2][9][14]. Group 1: Investor Engagement - The company will participate in the 2025 Shanghai Stock Exchange collective reception day and mid-year performance briefing on September 19, 2025, to address investor concerns [2][3]. - Investors can submit questions before the event via a dedicated webpage, and the company will respond to commonly raised issues during the briefing [2][3][4]. - The event will be held online from 15:00 to 17:00 on September 19, 2025, allowing for interactive communication [4][5]. Group 2: Product Approvals - The company's subsidiary, Sinopharm Group Rongsheng Pharmaceutical Co., Ltd., received approval for a supplementary application for sodium bicarbonate injection, which includes a new specification and has passed the consistency evaluation for generic drugs [9][10]. - The sodium bicarbonate injection is indicated for treating metabolic acidosis and preventing uric acid kidney stones, with a reported sales figure of approximately RMB 580 million in 2024 [11]. - The company has invested about RMB 2.7442 million in the research and development of the sodium bicarbonate injection's consistency evaluation [11]. Group 3: GMP Compliance - Sinopharm Group Weiqida Pharmaceutical Co., Ltd., another subsidiary, has passed the GMP compliance inspection for its raw material production lines, which is crucial for maintaining product quality [14][15]. - The inspection covered the production of acarbose, a drug used for diabetes treatment, and the facility has undergone significant renovations with an investment of approximately RMB 22.7604 million [15]. - This compliance is expected to enhance the company's product offerings and maintain stable production capabilities [16].